Literature DB >> 30509496

Integrative lipidomic and transcriptomic analysis of X-linked adrenoleukodystrophy reveals distinct lipidome signatures between adrenomyeloneuropathy and childhood cerebral adrenoleukodystrophy.

Dong-Kyu Lee1, Nguyen Phuoc Long2, Juwon Jung3, Tae Joon Kim2, Euiyeon Na2, Yun Pyo Kang2, Sung Won Kwon4, Jiho Jang5.   

Abstract

Precise pathophysiology with respect to the phenotypic variations and severity of X-ALD, specifically between adrenomyeloneuropathy (AMN) and childhood cerebral adrenoleukodystrophy (CCALD), has not been fully discovered. Herein, a systematic analysis using multi-layered lipidomics and transcriptomics was conducted to elucidate distinctive metabolic biosignatures among healthy control, AMN, and CCALD. Significant alterations regarding the accumulation of very long chain fatty acids were found in various lipid species such as phospholipids, glycerolipids, and sphingolipids. Remarkably, TG and CER that are physiologically essential were markedly down-regulated in CCALD than AMN. Transcriptomic analysis further supported the robustness of our findings by providing valuable information on the gene expressions of the regulatory factors. For instance, regulators of sphingolipid catabolism (SMPD1, CERK, and SPHK1) and TG anabolism (GPAM, GPAT2, and MBOAT2) were more up-regulated in AMN than in CCALD. These observations, among others, were in line with the recognized alterations of the associated lipidomes. In conclusion, the homeostatic imbalance of the complex lipid networks may be pathogenically important in X-ALD and the particular dysregulations of TG and CER may further influence the severity of CCALD among X-ALD patients.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Adrenomyeloneuropathy; Childhood cerebral adrenoleukodystrophy; Lipidomics; Transcriptomics; X-linked adrenoleukodystrophy

Mesh:

Substances:

Year:  2018        PMID: 30509496     DOI: 10.1016/j.bbrc.2018.11.123

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Identification of MBOAT2 as an Unfavorable Biomarker Correlated with KRAS Activation and Reduced CD8+ T-Cell Infiltration in Pancreatic Cancer.

Authors:  Zhenchong Li; Hongkai Zhuang; Xinming Chen; Yue Zhang; Zuyi Ma; Shujie Wang; Qian Yan; Zixuan Zhou; Shanzhou Huang; Chuanzhao Zhang; Baohua Hou
Journal:  J Oncol       Date:  2022-05-04       Impact factor: 4.501

Review 2.  X-linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies.

Authors:  Bela R Turk; Christiane Theda; Ali Fatemi; Ann B Moser
Journal:  Int J Dev Neurosci       Date:  2020-01-26       Impact factor: 2.457

3.  Hexacosenoyl-CoA is the most abundant very long-chain acyl-CoA in ATP binding cassette transporter D1-deficient cells.

Authors:  Kotaro Hama; Yuko Fujiwara; Shigeo Takashima; Yasuhiro Hayashi; Atsushi Yamashita; Nobuyuki Shimozawa; Kazuaki Yokoyama
Journal:  J Lipid Res       Date:  2020-02-19       Impact factor: 5.922

4.  An Integrative Data Mining and Omics-Based Translational Model for the Identification and Validation of Oncogenic Biomarkers of Pancreatic Cancer.

Authors:  Nguyen Phuoc Long; Kyung Hee Jung; Nguyen Hoang Anh; Hong Hua Yan; Tran Diem Nghi; Seongoh Park; Sang Jun Yoon; Jung Eun Min; Hyung Min Kim; Joo Han Lim; Joon Mee Kim; Johan Lim; Sanghyuk Lee; Soon-Sun Hong; Sung Won Kwon
Journal:  Cancers (Basel)       Date:  2019-01-29       Impact factor: 6.639

Review 5.  Steroidomics for the Prevention, Assessment, and Management of Cancers: A Systematic Review and Functional Analysis.

Authors:  Nguyen Hoang Anh; Nguyen Phuoc Long; Sun Jo Kim; Jung Eun Min; Sang Jun Yoon; Hyung Min Kim; Eugine Yang; Eun Sook Hwang; Jeong Hill Park; Soon-Sun Hong; Sung Won Kwon
Journal:  Metabolites       Date:  2019-09-21

Review 6.  Molecular Biomarkers for Adrenoleukodystrophy: An Unmet Need.

Authors:  Madison I J Honey; Yorrick R J Jaspers; Marc Engelen; Stephan Kemp; Irene C Huffnagel
Journal:  Cells       Date:  2021-12-06       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.